Cancer Patient in Remission Three Years after Stem Cell Implant of Immune Response
November 26th, 2007
The MAGE-A3 vaccine used in this study is manufactured by Glaxo-Smith-Kline, and is currently showing promise in Phase III trials in small cell lung cancer, the researchers said.